Highlights
This is my archive
IOB’s first spinout: RhyGaze AG
RhyGaze AG, a Spinout from the Institute of Molecular and Clinical Ophthalmology Basel (IOB), to advance groundbreaking gene therapy for treating blindness RhyGaze AG, a spinout from IOB, is developing a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness BGV and Novartis…
IOB’s winter highlights 2024
Career milestone Postdoctoral fellow Arjun Bharioke became Assistant Professor at the Medical University of South Carolina (MUSC, Charleston, USA). His new lab combines optical methods to interrogate circuits with computational modelling and simulations, to build an understanding of how cortical circuits form, respond to changes, and generate cognitive functions. Grants to IOB researchers…
Spotlight on vision science: IOB featured in Novartis Live N°19
We are delighted to be featured in the latest issue of Novartis Live magazine. The beautifully designed brochure highlights IOB’s work and mission, from groundbreaking work in optogenetics and gene therapy to our growing international team of researchers and to patient impact. We are thrilled and deeply grateful to see our…
IOB’s first spinout RhyGaze receives major funding
Funding enables progress of RhyGaze lead asset through early clinical trials Led by GV, series participants included Arch Venture Partners, F-Prime Capital and RhyGaze founding investors BioGeneration Ventures and Novartis Venture Fund RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured…
Better & more precise diagnostics of genetic diseases
Disease-causing mutations cluster in specific genes Some variants in human genes have no consequences – they are benign, while others cause disease – they are pathogenic and are called mutations. A team led by Carlo Rivolta, Head of our Ophthalmic Genetics Group, in collaboration with the teams of Andrea Superti-Furga…